The White House has indicated that it expects the US FDA to publish its final rule on regulating lab-developed tests by April. But first, the agency must consider thousands of comments that have poured in since the proposal was published in October.
As the Food and Drug Administration sifts through a tsunami of comments on its proposal to regulate lab-developed tests as medical devices, some are skeptical the agency can meet the White House’s expectations for finalizing the rule by April.
Allyson Mullen, a director at the law firm Hyman, Phelps & McNamara, who provides counsel to medical device manufacturers, says...
Create an account to read this article
Already a subscriber?
In revising the foundations of EU product legislation, the European Commission aims to increase harmonization, cut regulatory burdens and promote digital tools to boost compliance and safety.
The US Department of Health and Human Services has proposed cutting Medicare reimbursement for skin substitutes used in chronic wound care by up to 90%. The change aims to address rising costs but could harm patient access and treatment quality, prompting concerns from industry stakeholders.
The UK government’s response to MHRA public consultation on risk proportionate device routes to market and physical UKCA markings adds momentum to drive for modern, agile system. Another consultation in late 2025 will propose indefinite recognition of CE-marked devices in Great Britain.
The EU’s extra layer of checks on clinical evidence is proving a difficult, and sometimes humiliating process, for many device companies whose products have come under the spotlight.
